



February 25, 2021

The Honorable Rachel Prusak, Chair
House Health Care Committee
State Capitol
900 Court St NE
Salem, OR 97301

Dear Representative Prusak:

The Oregon Bioscience Association (OR Bio) and the Biotechnology Innovation Organization (BIO) respectfully oppose HB 2044, which would make a number of changes to existing Prescription Drug Price Transparency program.

Our organizations have repeatedly expressed on our members' behalf an interest in working with the Department of Consumer and Business Services (DCBS) on good faith compliance with the Prescription Drug Price Transparency program. Yet instead of working collaboratively to resolve problems with existing law, DCBS has put forth HB 2044 to establish new and questionable requirements. For a more thorough explanation of our concerns, please see the attached letter, which was submitted to DCBS on the draft of this bill last fall.

If you have any questions, please do not hesitate to contact us to discuss this further.

Sincerely,

A handwritten signature in blue ink that reads "Liisa Bozinovic".

Liisa Bozinovic
Chief Executive Officer
Oregon Bioscience Association

A handwritten signature in blue ink that reads "Brian Warren".

Brian Warren
Director, State Government Affairs
Biotechnology Innovation Organization

cc: Members, House Health Care Committee